Investor Relations

Home > Investor Relations > IR Library > Statements of Income and Loss (consolidated)

Statements of Income and Loss (consolidated)

(million yen) 
  FY2017
(2017/4/1-2018/3/31)
FY2018
(2018/4/1-2019/3/31)
Net sales 93,430 105,104
COGS 50,379 56,705
Gross Profit 43,050 48,399
SGA 31,407 32,431
Operating income 11,643 15,968
Non-operating income 1,632 3,234
Interest earned 58 48
Dividends earned 4 5
Subsidy income 590 466
Gain on revaluation of currency swaps - 1,144
Currency gain 603 958
Reversal of allowance for doubtful accounts - 315
Other non-operating income 374 296
Non-operating expenses 1.557 337
Interest paid 158 146
Loss on revaluation of currency swaps 1,334 -
Litigation settlement - 148
Other non-operating expenses 65 42
Ordinary income 11,717 18,865
Extraordinary gain 0 300
Gain on sale of fixed assets 0 2
Gain on abolishment of defined benefit plan - 298
Extraordinary loss 1,883 279
Loss on disposal of fixed assets 83 41
Loss on valuation of stocks of subsidiaries and affiliates - 62
Impairment loss 1,800 175
Net income before income taxes 9,833 18,886
Income taxes 3,411 5,595
Income taxes-deferred 73 185
Total income taxes 3,338 5,410
Income before minority interests 6,495 13,475
Profit attributable to owners of parent 6,495 13,475

Home > Investor Relations > IR Library > Statements of Income and Loss (consolidated)
© Copyright TOWA PHARMACEUTICAL CO.,LTD. All Rights Reserved.